Acute menopausal symptoms in young cancer survivors immediately following chemotherapy
| Autor: | Jennifer E. Mersereau, Martha B. Kole, Clarisa R. Gracia, Yasmin Gosiengfiao, Jill P. Ginsberg, Mary D. Sammel, H. Irene Su, Katherine E. Cameron |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Anti-Mullerian Hormone Sleep Wake Disorders Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment Libido Sweating Article 03 medical and health sciences Young Adult 0302 clinical medicine Risk Factors Internal medicine Neoplasms Antineoplastic Combined Chemotherapy Protocols medicine Prevalence Humans Prospective Studies Prospective cohort study Chemotherapy 030219 obstetrics & reproductive medicine Vasomotor business.industry Mood Disorders Incidence (epidemiology) Headache Cancer General Medicine medicine.disease Decreased Libido Menopause Oncology Premenopause 030220 oncology & carcinogenesis Case-Control Studies Hot Flashes Female Headaches medicine.symptom business |
| Popis: | Purpose: The aim of this study was to evaluate the prevalence of menopausal symptoms in young cancer survivors immediately following the completion of chemotherapy. Methods: This prospective cohort study followed 124 young females with a new diagnosis of cancer requiring chemotherapy to assess symptoms of menopause before treatment and immediately following chemotherapy. Symptoms were compared before and after treatment using the McNemar test and between cancer patients and 133 similar-aged healthy controls using Pearson χ2 and Fisher’s exact tests. Results: Participants undergoing cancer therapy reported more menopausal symptoms compared to controls prior to the initiation of any treatment (hot flashes or night sweats 33 vs. 7%, p < 0.01, trouble sleeping 57 vs. 31%, p < 0.01, headaches 50 vs. 35%, p = 0.02, and decreased libido 36 vs. 16%, p < 0.01) and also reported a greater prevalence of symptoms immediately after cancer therapy compared to pretreatment prevalence (vasomotor symptoms, p < 0.01, vaginal dryness, p < 0.01, decreased concentration, p < 0.01, and body aches, p = 0.01). Cancer patients with lower anti-Müllerian hormone (AMH) levels after treatment (p = 0.04), mood swings (OR 2.4, p = 0.03), feeling sad (OR 2.2, p = 0.04), trouble sleeping (OR 2.7, p = 0.02), and decreased libido (OR 3.0, p = 0.03) when controlled for age and cancer type, and the incidence of these symptoms was not affected by the use of systemic hormones or psychiatric medications. Treatment length, use of alkylating agents, pelvic radiation, and marital status were also not associated with the prevalence of menopausal symptoms. Conclusions: Premenopausal women with a new cancer diagnosis have more menopausal symptoms than females of similar age before and after cancer treatment, the effects of which are not mitigated by systemic hormone use. Decreased AMH levels were associated with an increased likelihood of reporting physiologic symptoms after therapy. Implications for Cancer Survivors: This information is imperative for counseling; ultimately, improved symptom management during and after cancer therapies will improve quality of life in young cancer survivors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|